Our research on the intersection of T-cell biology and regenerative medicine helped deliver a first-of-its-kind FDA approval for children with congenital athymia, an ultra-rare condition with little to no treatment options. Now, we’re continuing to harness our rare disease expertise to bring much-needed treatments to patients with rare respiratory conditions, with an initial focus on pulmonary arterial hypertension (PAH).
Learn more about our Phase 2 study exploring a new approach that may improve care for people with PAH, a rare respiratory disease with high mortality rates.
